Mimedx opened lower at $3.30, compared with its previous close of $3.32. In the last trading session, the stock traded between $3.21 and $3.34. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Mimedx is now worth
$ 39.55
Resulting in a loss of
$ 60.45 (60.45%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.09 (-2.56%)
Day High
$3.34
Day Low
$3.21
Day Open
$3.30
Prev Close
$3.32
Volume
11,39,017
1W Return
0.94%
1M Return
-32.95%
3M Return
-25.36%
6M Return
-9.13%
1Y Return
-57.10%
Market Cap ($ Mn)
472
PE Ratio
112.50
PB Ratio
3.04
PEG Ratio
4.33
ROE
21.92%
ROCE
25.81%
EPS (TTM)
$-0.06
1 Week
0.94%
1 Month
-32.95%
3 Months
-25.36%
6 Months
-9.13%
9 Months
-37.91%
MiMedx Group to participate in two investor conferences in November
Senior management to attend Canaccord MedTech Forum on November 11, 2026. Participation in Craig-Hallum Alpha Select Conference scheduled for November 17, 2026. Both events will be held in New York, NY. Webcast available for the Canaccord presentation at 9:00 am EST.
6 days agoMiMedx, Sanara receive US FTC second request for merger info
MiMedx Group and Sanara MedTech received a second request from the US Federal Trade Commission. The request demands additional information and documentary materials for the proposed merger. This regulatory step extends the timeline for the completion of the business combination.
27 days agoUS court vacates FDA ruling on MiMedx AXIOFILL classification
US federal court vacated FDA determinations on AXIOFILL's manipulation level and product classification. Court ruled FDA's biological product designation was arbitrary due to inconsistent treatment of similar devices. Case remanded to FDA for further consideration consistent with the court's legal framework. CEO Joseph H. Capper affirmed confidence in AXIOFILL's Section 361 HCT/P eligibility.
1mo agoMiMedx Group Q2 Results: Sales beat, EPS meets estimates
MiMedx Group's Q2 results show mixed signals: revenue of $64.362M beat estimates but fell 34.73% YoY, while adjusted EPS of $(0.05) met expectations despite a 150% drop from prior year profits.
3mo agoMiMedx Group affirms FY26 sales guidance of $260-290M
MiMedx Group reaffirms its FY2026 sales guidance of $260.000 million to $290.000 million, matching prior expectations. The outlook aligns with the consensus estimate of $269.440 million, reflecting stable revenue projections and no changes to previous financial targets.
3mo agoMiMedx posts $15M Q2 loss as Medicare cuts weigh on Wound sales
MiMedx Group posted a Q2 2026 net loss of $15 million as Medicare reimbursement cuts slashed Wound segment sales by 61% year-over-year. Despite this, the Surgical segment grew 15%, and Wound volume increased 22% sequentially, indicating market adaptation. Concurrently, MiMedx agreed to acquire Sanara MedTech for approximately $350 million to strengthen its surgical portfolio, with the deal expected to close by year-end.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Mimedx is now worth
$ 39.55
Resulting in a loss of
$ 60.45 (60.45%)
Note: Past profits do not guarantee future returns.
